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Abstract 
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) consists of a 
heterogeneous group of lymphomas. Patients generally show an aggressive clinical 
course and very poor outcome. Although the 2008 WHO classification of PTCL-NOS 
includes 3 variants, low-grade lymphoma is not included. Of 277 PTCL-NOS cases 
recorded in our consultation files, we examined the clinicopathological characteristics 
of 10 patients with T-cell lymphomas composed of small-sized cells with slight nuclear 
atypia. Eight patients showed extranodal involvement (5 patients, spleen; 3 patients, 
thyroid), and 5 patients were at clinical stage I or II. Histologically, all samples 
presented diffuse infiltrate of small lymphoid cells, with few mitotic figures. 
Immunohistologically, all samples were positive for CD3, and CD20 was detected in 5 
samples. All samples showed a low Ki-67 labeling index (mean, 1.05%), and 7 samples 
were positive for central memory T-cell markers. Clonal T-cell receptor γ chain and/or 
α-β chain gene rearrangements were detected in all 10 patients. Five patients received 
chemotherapy, whereas for 3 patients, treatment consisted only of observation following 
surgical resection of the spleen or thyroid. Nine patients were alive at a median 
follow-up time of 19.5 months, whereas 1 patient died of an unrelated disease. The 
present study strongly indicates that T-cell lymphoma with small-sized lymphoma cells 
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and a low Ki-67 labeling index is a distinct variant. Recognition of this novel lymphoma 
subtype, which should not be defined merely as PTCL-NOS, should be seriously 
considered. 
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Introduction 
Peripheral T-cell lymphomas, not otherwise specified (PTCL-NOS) constitute a 
heterogeneous group of nodal and extranodal mature T-cell lymphomas that do not 
correspond to any of the specifically defined entities of mature T-cell lymphoma in the 
current WHO Classification system [1]. PTCL-NOS account for 25.9% of PTCLs 
according to the International Peripheral T-cell Lymphoma Project [2] and 7.21% of all 
lymphomas in Japan [3].  
PTCL-NOS include lymphomas that can be categorized into various groups 
genetically and biologically; therefore, this category has been referred to as a 
“wastebasket” category [4]. Histologically, PTCL-NOS show paracortical or diffuse 
infiltrates, with effacement of the normal lymph-node architecture. In most cases, 
numerous medium-sized or large cells with many mitotic figures are noted. In rare cases, 
small lymphoid cells predominate, but the cells show atypia and have irregular nuclei. 
Although PTCL-NOS is a heterogeneous category, it is generally thought that 
PTCL-NOS are aggressive lymphomas characterized by a poor response to therapy, 
frequent relapses, and a low 5-year overall survival rate [5]. 
In the present study, we described a group of 10 patients that was morphologically and 
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phenotypically unique, having small, monotonous lymphoid cells characterized by 
slight nuclear atypia, a low Ki-67 labeling index (LI), and good prognosis compared to 
those of typical PTCL-NOS patients. 
To the best of our knowledge, no previous clinicopathological studies have focused on 
these unique T-cell lymphomas, excluding a few case reports [6, 7]. The 
immunohistochemical and genotypic characteristics of this disease were examined in 
the current study, and we attempted to determine the clinical significance of these 
findings during the clinical follow-up. 
 
Materials and Methods 
Patient selection and clinical data 
 We chose 10 PTCL-NOS patients characterized by an infiltrate of monotonous, 
small-sized lymphoid cells with slight nuclear atypia and a low Ki-67 LI (<5%), from 
among 277 cases of PTCL-NOS recorded in the 2006–2011 pathology consultation files 
of the Department of Pathology, Okayama University Graduate School of Medicine, 
Dentistry, and Pharmaceutical Sciences. Among all 277 cases, no patients had the same 
histopathology but a higher Ki-67 LI. Fourteen of the 277 cases had small to medium 
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sized lymphoid cells with irregular nuclei, and showed high Ki-67 LI (>30%). Therefore, 
we excluded these cases in the present study. There was no case composed of 
large-sized lymphoid cells and showing a low Ki-67 LI. Because the samples of all 10 
patients that we included had a Ki-67 LI of 5% or less in our study, we defined the 
cut-off as 5%, although it is commonly placed at 30% [8]. Clinical data were available 
for all patients. We collected data on age, gender, complete blood count, lactate 
dehydrogenase (LDH) level, B symptoms, disease at other sites, bone marrow 
involvement, performance status (PS), Ann Arbor stage [9], international prognostic 
index (IPI) [10], prognostic index for PTCL-unspecified (PIT) [11], history of prior 
immunosuppressive therapy or immune system disorder, type of treatment, response to 
therapy, date of last follow-up, and status. HIV-positive or human T-cell leukemia 
virus-positive patients were excluded. Informed consent for examination was obtained 
for the use of all samples.  
 
Immunohistochemistry and hybridization studies 
Tissue samples were fixed in 10% formalin and embedded in paraffin. Staining was 
performed using paraffin sections with an automated Bond-max stainer (Leica 
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Biosystems, Melbourne, Vic., Australia). The primary antibodies and probes used are 
summarized in Table 1. For CD20, CD3, CD5, CD7, CD4, CD8, CD79a, CD45RO, 
CCR7, CD62L, PD1, CD56, CD57, CXCL13, granzyme B, TIA-1, TCRγ, TCRδ, and 
TCRβ antigens, positivity was identified when at least 30% of the lymphoma cells were 
positive for their respective antibodies. The Ki-67 LI was determined by counting at 
least 1,000 tumor cells in each sample, and the index was calculated as a percentage. 
For flow cytometry (FCM), the following antibodies were used: CD2, CD3, CD4, 
CD5, CD7, CD8, CD10, CD19, CD20, CD22, and CD23, along with Igκ and Igλ light 
chains. 
For the indirect double immunofluorescence study, paraffin sections were stained with 
CD3 and CD20. The following primary antibodies (clone, dilutions) were used: CD20 
(L26, 1:200; Novocastra, Newcastle-upon-Tyne, UK) and CD3 (rabbit polyclonal, 
1:100; Abcam, Tokyo, Japan). The indirect double immunofluorescence study was 
performed according to standard procedures, as described previously [12]. 
 
Molecular genetic analysis 
Molecular genetic analysis was performed using polymerase chain reaction (PCR) or 
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Southern blot hybridization. PCR was used in the analysis of gene rearrangements of 
both TCR and the immunoglobulin heavy chain (IgH). PCR was performed according to 
standard procedures, as described previously [13-16]. For Southern blot hybridization, 
high-molecular-weight genomic DNA was extracted from fresh tissue taken from the 
patients and used for the detection of TCRγ gene rearrangements or IgH gene 
rearrangements, according to a method described previously [17]. 
 
Results 
Patient summary 
The clinical features of the 10 patients are summarized in Table 2. The age of the 
patients (5 men and 5 women) ranged from 41 to 82 years, with a median age of 61.5 
years. Eight patients showed extranodal site involvement, with the extranodal site being 
the spleen in most cases (5 patients), followed by the thyroid gland (3 patients). 
Additionally, in 2 of 5 patients who had an affected spleen, the disease was localized 
to that organ. Those patients with thyroid gland involvement also demonstrated 
involvement of the regional lymph nodes (2 patients) or systemic lymph nodes (1 
patient). Three of 10 patients had systemic lymph node involvement. Bone marrow 
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involvement was observed in 3 of 9 patients. One patient increased lymphocyte counts, 
and in another patient, 2% of cells in the peripheral blood had chromosomal 
abnormalities. We confirmed there was no azurophilic granule or prominent nucleoli in 
the tumor cell, or atypical lymphocytes in any of the patients' smears. Results for 
clinical stage were as follows: stage I, 2 patients; stage II, 3 patients; stage III, 1 patient; 
and stage IV, 4 patients. Nine patients had an IPI of low or low-intermediate risk. In the 
PIT, 2 patients were group 1, and 6 patients were group 2. Patient no. 5 had B symptoms 
and hypergammaglobulinemia, whereas patient no. 10 had autoimmune hemolytic 
anemia and elevated serum LDH. None of the patients demonstrated bulky disease (size 
of lymph node ≥ 10 cm) with a history of prior immunosuppressive therapy or immune 
system disorder. 
Compared to the study of PTCL-NOS by the international PTCL-NOS project [5], our 
patient series had low IPI scores (p < 0.001), low PIT group scores (p = 0.002), and a 
normal LDH level (p = 0.035; Table 3). Furthermore, compared with another report that 
described clinical information in more detail [18], our patient series had low clinical 
stages (p = 0.025), low IPI scores (p = 0.015), and a normal LDH level (p = 0.025; 
Table 3). 
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Morphological and immunophenotypic features 
Regardless of whether the lesion was nodal or extranodal, all samples presented 
diffuse infiltrate of small lymphoid cells (Figure 1 a–f). These cells had oval or slightly 
irregular nuclei and pale cytoplasm. In cases with thyroid lesions, tumor cells infiltrated 
the follicular epithelium, resembling a lymphoepithelial lesion involved in 
mucosa-associated lymphoid tissue (MALT) lymphoma (Figure 1 d). Samples from all 
patients were positive for CD3, TCRβ, and surface antigen of central memory T-cells 
(CD45RO and CCR7). Seven samples were positive for another antigen of central 
memory T-cells (CD62L). Three of the 10 samples demonstrated either complete loss or 
decreased staining intensity for CD5 or CD7. Half of the samples showed the helper 
T-cell phenotype (CD4+, CD8-), whereas the other half showed the cytotoxic T-cell 
phenotype (CD4-, CD8+). Only the clinical stage tended to be high in the cytotoxic 
phenotype samples (P=0.07), however we found no significant differences in 
clinicopathological data between samples with the cytotoxic T-cell phenotype and those 
with the helper T-cell phenotype. All CD8-positive samples were positive for granzyme 
B or TIA-1. Both T follicular helper cell markers (PD1 and CXCL13) were positive in 3 
samples, and these samples were also positive for CD4. Although CD57 was positive in 
patient no. 3, this patient did not show any LGL, and the patient's lymphocyte counts 
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did not increase. All samples in the study were negative for CD79a, CD56, TCRδ, TCRγ, 
and EBER ISH. An overview of marker expression is presented in Table 4, and Figure 1 
g-x shows the immunohistochemical staining of patient no. 9. Mitosis was very rare, 
and Ki-67 LI was low (range, 0.28–3.04%; mean, 1.05%; Table 4).  
Five samples had CD20 expression. Figure 2 a–d shows CD20 expression, as 
measured using flow cytometry, and the double immunofluorescent study of CD3 
(green) and CD20 (red) in patient no. 7. We found that CD20 was coexpressed in 
CD3-positive tumor cells. 
 
Molecular genetic findings 
TCRγ chain and/or TCRα-βchain gene rearrangements were detected in all 10 patients. 
In 7 of these patients, these rearrangements were detected using PCR analysis; in the 
remaining 3 patients, the rearrangements were detected using Southern blot 
hybridization (Figure 3 a–b). However, we could not detect any immunoglobulin 
heavy-chain gene rearrangements in any of the 10 patients, using either method. 
G-banding karyotype analysis was performed in 3 patients. In patient no. 9, this 
analysis showed abnormal karyotypes (Table 4). In patient no. 6, there was only a single 
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cell with an apparent chromosomal abnormality.  
 
Response to treatment and survival 
The median follow-up period was 19.5 months. Only patient no. 10 died, and this 
death resulted from autoimmune hemolytic anemia. The other 9 patients are alive, with 
or without disease. Treatment and outcome data for all patients are shown in Table 2. 
Six patients were treated with chemotherapy or allogeneic bone marrow transplantation, 
and 4 achieved complete response (CR). Three patients received only observation after 
splenectomy or thyroidectomy, and did not experience recurrence. 
 
Discussion 
In this study, we presented a new, distinct subgroup of T-cell lymphomas with good 
prognosis; this subgroup appears to be a subset of PTCL-NOS. The 10 patients with this 
condition showed similar histological findings, and the disease was characterized by 
infiltration of small lymphoid cells with slight nuclear atypia and low Ki-67 LI. Half of 
the patient samples showed the helper T-cell phenotype (CD4+), and the other half 
showed the cytotoxic phenotype (CD8+). Cytotoxic molecule positive PTCL-NOS was 
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associated with several clinical factors that indicate poor prognosis [18, 19]. In this 
study, however, we could find no significant differences in clinicopathological data 
between samples with the cytotoxic phenotype and those with the helper T-cell 
phenotype. In addition, patient no. 8, who had the cytotoxic phenotype, is alive and 
without disease after splenectomy alone. This clinical behavior is unusual in general for 
PTCL-NOS. Actually, the cytotoxic markers become prognostic factors in PTCL-NOS, 
but in our present series, the cytotoxic markers might have displayed a different 
behavior. 
It may be necessary to distinguish the disease observed in our patient series from 
T-cell large granular lymphocytic leukemia (T-LGL), T-cell prolymphocytic leukemia 
(T-PLL), and chronic lymphoproliferative disorders of NK cells (CLPD-NK) due to the 
fact that small lymphoid cells proliferate. T-LGL patients were distinguished from our 
patient series by their large granules and the displayed phenotype. T-PLL usually had 
elevated lymphocyte counts (>100 ×10
3μl) and prominent nucleoli in lymphoid cells (1). 
CLPD-NK are characterized by an increase in peripheral blood NK cells (>2 × 10
3
 μl) 
and are positive for CD16 and CD56 (1). On the other hand, it may be necessary to 
distinguish our patient series from T-LGL, T-PLL, and chronic adult T-cell 
leukemia/lymphoma (ATLL) due to the fact that the clinical course was indolent. Our 
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patient series can be distinguished by the T-LGL and T-PLL in their smear and the 
phenotype described above. ATLL showed monoclonal integration of HTLV-1. All 
patients in our series were negative for HTLV-1. Therefore, we excluded chronic ATLL.  
While some patients were treated with chemotherapy and 1 patient received bone 
marrow transplantation, all patients, excluding patient no. 3, are alive, with or without 
disease, and 3 patients did not relapse after surgical resection. We thought that these 
clinical behaviors differentiated our series from the general PTCL-NOS population. 
CD20, a selective marker for B-cells, was expressed in half of our patient series. The 
presence of CD20 is generally considered specific for the B-cell lineage on both benign 
and neoplastic lymphocytes. T-cell lymphoma with expression of CD20 is a rare, but 
well-recognized phenomenon, and CD20 expression has been reported in some patients 
[6, 7, 20-22]. Although the clinicopathological spectrum of CD20-positive T-cell 
lymphomas is still not well understood, this condition is known to occur frequently in 
elderly men and to show an aggressive clinical course in many patients [7]  
Another interesting result of the immunohistochemical staining was that all patient 
samples were found to be positive for CD45RO and CCR7, whereas 7 were positive for 
CD62L. These antibodies are expressed in central memory T-cells (TCM). Naive T-cells 
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differentiate into lymphocytes of various type such as TCM, effector memory T-cells, 
regulatory T-cells, and follicular helper T-cells after antigen stimulation[23]. In a study 
of helper T-cell differentiation of PTCL-NOS, it was reported that only 2 of 10 patients 
expressed both CCR7 and CD62L [24]. In contrast, 7 of the patients in our series 
showed samples that were positive for both of these antigens. This result suggests that 
this type of indolent T-cell lymphoma derives from organ-specific TCM. Furthermore, 
this characteristic suggests that this type of indolent T-cell lymphoma is localized to 
extranodal sites that are somewhat similar to MALT lymphoma [1, 25, 26]. 
Although PTCL-NOSs are predominantly nodal lymphomas [27], there was extensive 
extranodal site involvement in our patient series. PTCL-NOS at the extranodal sites, 
especially the spleen and the thyroid, might be associated with a high frequency of this 
type of indolent T-cell lymphoma. Physicians may need to pay careful attention to 
PTCL-NOS in these sites because of the possibilities of indolent T-cell lymphoma. 
Xiao et al. reported a case of T-cell lymphoma with indolent clinical behavior that was 
positive for CD20 [6]. Rahemtullah et al. described a 9-patient series of CD20-positive 
T-cell lymphomas, in which 1 patient presented with the same morphological and 
immunophenotypical characters as the patients in our present series [7]. These other 2 
reports may concern the same subset of patients as does our series. Perry et al. reported 
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7 cases of indolent T-cell lymphoproliferative disease of the gastrointestinal tract [28], 
and these patient samples consisted of small lymphoid cells with slightly irregular 
nuclei, clear cytoplasm, and low Ki-67 LI (5-10%). This lymphoproliferative disease 
might be similar to the one occurring in our patient series. To the best of our knowledge, 
ours is the first report to describe a clinicopathological analysis of this new, distinct 
subgroup of T-cell lymphomas. 
In conclusion, indolent T-cell lymphoma has distinct morphological, 
immunophenotypical, and clinical outcomes. Therefore, it may need to be classified as 
an independent disease. More cases and long-term prognoses must be evaluated to 
clarify the pathophysiology of this subgroup.  
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Table 1. Antibodies used for immunohistochemical analysis 
Antibody or Probe Source Clone Dilution
CD20 Novocastra, Newcastle-upon-Tyne, UK L26 1:200
CD3 Novocastra LN10 1:200
CD5 Novocastra 4C7 1:100
CD7 Novocastra CD7-580 1:50
CD8 Nichirei, Tokyo, Japan C8/144B 1:100
CD4 Nichirei 1F6 1:40
CD79a Dako, Glostrup, Denmark JCB117 1:40
CD45RO Dako UCHL1 1:50
CD62L Abcam, Tokyo, Japan rabbit polyclonal 1:100
CD56 Leica Biosystems, Melbourne, Vic., Australia 1B6 1:30
CD57 Leica Biosystems NK-1 1:50
granzyme B Nichirei GrB-7 ready to use
TIA-1 Beckman Coulter, Brea, CA, USA 2G9 1:500
PD1 Abcam, Tokyo, Japan NAT 1:200
CCR7 Epitomics, CA, USA Y59 1:5000
CXCL13 R&D Systems, Minneapolis, MN, USA goat polyclonal 1:50
Ki-67 Novocastra MIB-1 1:5000
Human Pan TCRγδ Thermo scientific, Waltham, MA, USA 5A6.E9 1:20
TCR1151 Thermo scientific 8A3 1:50
TCR1153 Thermo scientific γ3.20 1:80
EBV-encoded small RNA INFORM EBER, Leica Biosystems - -
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Table 3. Comparison of our patient series and PTCL-NOS
Our patient series
n/N(%) n/N(%) p n/N(%) p
Age；median 61.5 60 - 60 -
Male: female 1:1 1.9:1 0.7 a 3:2 0.714 a
LDH >normal, 1/10(10) 158/323(49) 0.035 a 42/90(47) 0.025 a
Performance status ≥2 0/10(0) 60/334(18) 0.293 a 20/93(22) 0.103 a
B symptoms 1/10(10) 118/340(35) 0.198 a 31/88(35) 0.1 a
bulky disease (≥ 10 cm) 0/10(0) 19/285(7) 0.85 a 11/85(13) 0.273 a
BM involvement 3/9(33) 68/322(21) 0.639 a 31/85(36) 0.581 a
   I 2/10(20) 45/334(14) 1/93(1)
  II 3/10(30) 57/334(17) b 19/93(20) b
  III/ IV 5/10(50) 232/334(69) 73/93(79)
IPI , Score
0/1 7/10(70) -  (28) 24/90(27)
2 2/10(20) -  (35) 31/90(34)
3 0/10(0) -  (22) 23/90(26)
4/5 1/10(10) -  (15) 12/90(13)
PIT, group
1 2/9(22) -  (20) 17/85(20)
2 6/9(67) -  (38) 27/85(32)
3 0/9(0) -  (29) 29/85(34)
4 1/9(11) -  (13) 12/85(14)
b
 P  value by  Mann-Whitney nonparametric test
PTCL-NOS [5] PTCL/U [18]
a
 P  value by Fisher’s exact probability test or chi-square for independence test
Stage
[5] Weisenburger DD et al. 2011
[18] Went P et al. 2006
0.213
< .001
0.002
b
b
b
b
0.025
0.015
0.165
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Figure legends 
Figure 1. Histopathology of various lesions and immunostaining of samples. 
(a, c, and e: original magnification ×10 objective; x: ×20; b, d, and f-w: ×40) 
(a, b) Lymph nodes of patient no. 6 displayed diffuse infiltration of small lymphoid cells. 
These lymphoid cells showed oval or slightly irregular nuclei and pale cytoplasm on 
hematoxylin and eosin staining. 
(c, d) Thyroid gland of patient no. 2: the thyroid follicle was present between the tumor 
cells, and a part of the residual follicle presented lymphoepithelial lesions. This was 
observed more clearly on CK AE1/AE3 staining (inset). 
(e, f) Spleen of patient no. 9: the tumor cells diffusely infiltrated the red pulp. 
(g-w) Immunohistochemical results of patient no. 9: The tumor cells were positive for 
CD3 (g), weakly positive for CD20 (h), negative for CD79a (i), positive for CD5 (j), 
negative for CD7 (k), negative for CD4 (l), positive for CD8 (m), positive for TIA-1 (n), 
positive for granzyme B (o), positive for CCR7 (p), positive for CD62L (q), negative for 
CXCL13 (r), weakly positive for PD1 (s), negative for CD56 (t), negative for CD57 (u), 
positive for αβ-TCR (v), and negative for γδ-TCR (w).  
(x) The Ki-67 labeling index was very low at 0.28%. 
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Figure 2. Analysis of aberrant expression of CD20 from patient no. 7. 
(a) The 2-color flow cytometry of the lymph node. The tumor cell group was positive 
for CD3, CD5, CD20, CD8, CD2, and CD7.  
(b-d) On double immunofluorescence of CD3 (green, b) and CD20 (red, c), almost all 
CD3-positive cells were positive for CD20 in a merge image (yellow, d). 
 
Figure 3. Molecular genetic analysis 
(a) Oligoclonal bands around 210-bp were detected using polymerase chain reaction 
analysis (patient no. 7).  
(b) Southern blot analysis of DNA from patient no. 3 with the Jγ probe (left) and the 
Cβ1 probe (right). Germline bands are indicated by black arrows and rearranged bands 
by red arrows. Clonal bands were seen in the lane 2 of the Jγ probe and lane 1 and 2 of 
the Cβ1 probe. 
 
